NCT02972372 Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal Cancer
| NCT ID | NCT02972372 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of Henan University of Science and Technology |
| Condition | Esophagus Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 196 participants |
| Start Date | 2016-11 |
| Primary Completion | 2025-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 196 participants in total. It began in 2016-11 with a primary completion date of 2025-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to compare outcomes in Chinese patients with locally advanced resectable esophageal squamous cell cancer who have received either surgery or definitive chemoradiation (CRT) by the randomized, open-label, multicenter trial.
Eligibility Criteria
Inclusion Criteria: * Chinese * esophageal squamous cell cancer * mid or lower esophageal cancer * tumor is resectable disease * clinical stage: cT1bN+Mo, or cT2-4aN0-2M0 Exclusion Criteria: * who had distant metastasis to solid visceral organs or local invasion into trachea, descending aorta, or recurrent laryngeal nerve. * who had a serious premorbid condition or a poor physical status that compromised a thoracotomy.
Contact & Investigator
Shegan Gao, MD, PhD
STUDY CHAIR
The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology
Frequently Asked Questions
Who can join the NCT02972372 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Esophagus Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02972372 currently recruiting?
Yes, NCT02972372 is actively recruiting participants. Contact the research team at gsg112258@163.com for enrollment information.
Where is the NCT02972372 trial being conducted?
This trial is being conducted at Anyang, China, Luoyang, China.
Who is sponsoring the NCT02972372 clinical trial?
NCT02972372 is sponsored by The First Affiliated Hospital of Henan University of Science and Technology. The principal investigator is Shegan Gao, MD, PhD at The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology. The trial plans to enroll 196 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.